Breaking AI & Tech News Analyzed

Scientists have unveiled a new giant sauropod from Thailand, naming it Nagatitan chaiyaphumensis. The discovery, detailed in Scientific Reports, positions the species as the largest known dinosaur from Southeast Asia and offers fresh clues about the region’s prehistoric environment.Discovery of Nagatitan chaiyaphumensis in Northeast ThailandThe fossil remains were first spotted by local residents a decade ago in the Chaiyaphum province, but systematic excavation only concluded in 2024. The specimen, recovered from one of the youngest Thai rock formations, displayed unique skeletal features that warranted classification as a new species within the sauropod lineage.Size and Weight Estimates Put Nagatitan Among the Largest SauropodsMeasurements indicate the herbivore stretched 27 metres (89 feet) long and weighed about 27 tonnes, comparable to the mass of nine adult elephants. Researchers note it likely outweighed the famous Diplodocus cast “Dippy” at the Natural History Museum by at least 10 tonnes. The animal is dated to have roamed the area between 100 and 120 million years ago, during the mid‑Cretaceous.Implications for Southeast Asian Paleontology and Regional HeritageAs the biggest dinosaur ever found in Southeast Asia, Nagatitan expands the known geographic range of late‑surviving sauropods, which were thought to have largely disappeared from the region when it became a shallow sea in the Cretaceous. The find underscores Thailand’s growing importance as a paleontological hotspot and adds to the modest list of 14 named Thai dinosaurs.Future Research Directions and Tourist OpportunitiesLead author Thitiwoot Sethapanichsakul—a University College London PhD student—suggests further fieldwork could clarify the dinosaur’s feeding habits, which likely involved bulk browsing of conifers and seed ferns. A life‑size reconstruction now stands at Bangkok’s Thainosaur Museum, hinting at increased scientific tourism and educational outreach in the region.

The Graduation Contrast: Celebration vs. RealityFor decades, the ritual of graduation in New York City’s Washington Square Park symbolized a seamless transition from academia to the workforce. However, for the class of 2026, that transition has become a precarious journey. While the visual spectacle of caps and gowns remains, the underlying economic reality has shifted dramatically. The joy of the ceremony is increasingly dampened by a 'no-hire, no-fire' environment where the churn of the labor market has stalled, leaving millions of new graduates competing for a shrinking pool of entry-level opportunities.The 'No-Hire, No-Fire' Labor StagnationThe current economic climate is defined by a paradox: there are still millions of open jobs, but the barrier to entry for new graduates has never been higher. According to the United States Bureau of Labor Statistics, while there are 6.9 million open jobs in March, hirings only increased marginally by 655,000 to 5.6 million. This stagnation suggests that the labor market is effectively frozen for new entrants.Job Growth Slowdown: The US economy added an average of 68,000 jobs per month in 2026, a sharp decline from 186,000 in 2024 and 251,000 in 2023.Sectoral Shifts: While healthcare and retail saw growth, white-collar sectors like financial activities and information services shed jobs.The Churn Rate: The quits rate is down, indicating that workers are staying in their positions rather than switching, which leaves little room for new graduates to move up.The Federal Workforce ShrinkageA critical factor exacerbating the shortage of entry-level roles is the drastic contraction of the federal government workforce. Since October 2024, the federal workforce has declined by 348,000, with an additional 9,000 jobs lost in April alone. This exodus is largely driven by government funding cuts, including a $4bn reduction in research funds from the National Institutes of Health (NIH).These cuts have forced major universities, including Duke University and Harvard University, to implement hiring freezes. Consequently, recent graduates like Julie Patel and Molly Howard are not only competing with their peers but also with experienced professionals displaced by these funding cuts, creating a 'last-in, first-out' dynamic in the public health and research sectors.AI as the New GatekeeperPerhaps the most disruptive force reshaping the entry-level landscape is artificial intelligence. The analysis from the Stanford Digital Economy Lab reveals a 16 percent decline in relative employment for early-career workers, particularly in software engineering and customer service. This trend is expected to intensify, with Goldman Sachs forecasting an average of 16,000 jobs cut monthly due to AI advancements.The impact is twofold: entry-level roles are being eliminated and replaced by automation, while demand for experienced workers remains stable. Furthermore, the hiring process itself has become a minefield. Applicants are now facing AI recruiters and an influx of 'fake applicants,' leading to response rates as low as 10 to 12 percent for recent graduates applying to 60 roles.Navigating the Post-Pandemic CycleDespite the grim outlook, experts argue that this is not uncharted territory. The unemployment rate for recent college graduates is currently at 5.6 percent, higher than the general population's 4.2 percent, but historically manageable compared to the 13.4 percent peak during the COVID-19 pandemic. However, underemployment remains a persistent issue at 41 percent.The consensus among university leaders is that while the structural challenges of AI and political uncertainty are new, the resilience of graduates is not. As Christopher Davis of LeMoyne-Owen College notes, the degree may secure an interview, but it is the 'soft skills'—particularly in-person networking—that will ultimately determine success in this hyper-competitive market.

The Shift in Canada's Defence Strategy Canada has announced plans to buy a fleet of early warning planes from Sweden's Saab rather than a competing option from Boeing as it seeks to reduce its reliance on the United States. Details of the Deal Prime Minister Mark Carney said on Wednesday that Canada would opt for Saab's GlobalEye, which is based on Bombardier's Global 6500 jet. Boeing's E-7 Wedgetail plane – which has suffered from delays and cost overruns – had also been in contention. Saab's GlobalEye will be a key resource for the Canadian Armed Forces to detect and deter threats across the Arctic. The Prime Minister pledged in March that Canada would take full responsibility for protecting its vast Arctic territory. The Data Analysis Although Carney did not give details of the fleet size or the cost of a potential contract, military officials had earlier said they were looking to buy six early warning aircraft. The Impact Analysis Philippe Lagasse, associate director of international affairs at Ottawa's Carleton University, said Canada's decision to buy the GlobalEye planes was “an important test case for the Carney government's policy of pivoting away from American military capability”. This decision confirms Canada's relationship with Sweden, a new NATO ally that has also been eager to strengthen its ties to the Canadian military. The Prediction Saab is also in the running to sell Canada some of its Gripen fighters. Still, Lagasse of Carleton University said he expected Canada would ultimately decide to stick with a fleet of F-35 jets rather than splitting the fleet by buying some Saab Gripens.

The AI Startup Valuation ShiftAnthropic has usurped OpenAI as the world's most valuable artificial intelligence startup, soaring to a $965bn valuation ahead of expected public listings by the rival firms. Anthropic, the maker of the Claude family of chatbots, said on Thursday that it had raised $65bn from private investors after a fundraising round led by Altimeter Capital, Greenoaks, Dragoneer and Sequoia Capital.Funding and Leadership PositionThe announcement catapults Anthropic, led by CEO and cofounder Dario Amodei, ahead of ChatGPT maker OpenAI in value, which attracted an $852bn valuation in its last fundraising round in March. "This funding will help us serve the historic demand we are experiencing, stay at the research frontier, and bring Claude to more of the places where work happens," Anthropic's Chief Financial Officer Krishna Rao said in a statement.Market Recognition and AdoptionAltimeter Capital CEO Brad Gerstner hailed the adoption of Claude among the "world's most demanding organisations" as evidence of Anthropic's command in the field. "This momentum positions Anthropic to lead the next phase of AI innovation and capture the enormous opportunity ahead," Gerstner said.Rapid Growth and Market PositionFounded in 2021 by former OpenAI researchers, Anthropic has rapidly emerged as one of the leading players in Silicon Valley's scramble to dominate AI. Anthropic's Claude, first launched in 2023, is among the most popular AI models worldwide. In March, the San Francisco-based company said that the chatbot was receiving more than 1 million new sign-ups each day.Challenges and Recent DevelopmentsWhile achieving stellar success in rapid time, Anthropic has also faced challenges – in particular, a high-profile dispute with US President Donald Trump's administration, which has labelled the firm a "supply chain risk" over its refusal to allow unrestricted access to its tools for military purposes. Anthropic unveiled its latest iteration of Claude, Opus 4.8, in a separate announcement on Thursday, calling it a "modest but tangible improvement" on its predecessor.Future Outlook and Market DynamicsAnthropic, OpenAI and Elon Musk's rocket company SpaceX are all expected to go public in the near future in what are expected to be among the biggest initial public offerings in history. Jay R Ritter, an emeritus professor at the University of Florida who specialises in IPOs, said Anthropic has generated a lot of market excitement due to its widespread use by companies for software coding. "This is a big market where apparently Anthropic has the best product," Ritter told Al Jazeera.Valuation Trends and Market Analysis"The increase in valuation in a short period of time is unprecedented for a startup, although publicly traded tech companies such as SK Hynix, Nvidia, and Alphabet have seen even bigger increases, although not as much in percentage terms," Ritter said, referring to the South Korean and US chip giants, and Google's parent company. While it remains to be seen whether the massive investments pouring into AI are creating a bubble, Ritter said, the handful of successful firms that are likely to emerge in the field could see enormous profits.Industry Consolidation and Future Prospects"Nobody wants to use the eighth best product, so these companies are either one of the handful of successful firms, or they will have a zero market share," he said. "The tech industry is different than the restaurant industry, where there are not large economies of scale, and where competition limits the profit margins."

The Pavlovian Paradox: Mosquitoes Learn to Associate DEET with FoodFor decades, the efficacy of DEET (N,N-diethyl-meta-toluamide) has been attributed solely to its chemical properties, which are believed to either repel insects or block their ability to detect humans. However, a new study led by Professor Claudio Lazzari from the University of Tours suggests a more complex behavioral interaction. The research indicates that mosquitoes can learn to associate the scent of DEET with the presence of a blood meal, effectively turning a repellent into a lure through a process similar to Pavlovian conditioning.Experimental Evidence: From Repellent to LureThe study, published in the Journal of Experimental Biology, involved trapping mosquitoes and presenting them with warm blood that was just out of reach. The insects were simultaneously exposed to DEET. The results demonstrated a significant shift in behavior:Trained Group: 60% of mosquitoes that fed while exposed to DEET subsequently attempted to bite when exposed to the repellent alone.Control Groups: Significantly lower percentages were observed in untrained insects (17%) and those with prior exposure to DEET alone (13%).In a real-world test, nearly 60% of the trained mosquitoes attempted to bite a researcher's DEET-treated hand, whereas untrained mosquitoes universally targeted the untreated hand.Redefining Insect Control StrategiesThis discovery represents a significant shift in our understanding of how repellents work. It suggests that the reaction to DEET is not merely a chemical aversion but can be modified by experience. Experts, including Dr. Nina Stanczyk of ETH Zürich, emphasize that while the learning ability of mosquitoes is impressive, the implications for public health are nuanced. The study highlights that repellents may function differently depending on the context of the mosquito's previous interactions with humans.Future Outlook for TravelersDespite the alarming findings, experts urge travelers not to abandon DEET. The consensus is that this phenomenon occurs under specific laboratory conditions and is unlikely to happen frequently in the wild due to the variability of repellents encountered during different blood meals. The key takeaway for the future is the importance of consistent application. As noted by the researchers, the risk of association is highest when the repellent starts to wear off, reinforcing the need for regular reapplication to maintain protection.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

The Concept of 'Mind Children' A few months ago, an AI researcher from Europe attended a dinner party in Silicon Valley. During one of the many courses, the host addressed his guests, all of whom worked in AI. The researcher paraphrased his message like this: “Isn’t it amazing that we are the last generation of humans who will need to think about procreating biologically? We were lucky enough to be born at a time where we can simply upload our consciousnesses instead.” The Book That Sparked the Conversation The book in question was Hans Moravec’s Mind Children: The Future of Robot and Human Intelligence, which was first published in 1988, and which at the time, according to economist and futurist Robin Hanson of George Mason University, caused a big splash in a small pond – the community of robotics and machine-learning experts to which Moravec belonged. The Data Analysis Moravec’s book is more philosophical treatise than technological manual, but the central idea is that cultural evolution has long since taken over from biological evolution as the most powerful force shaping humanity. The logical extrapolation of this is that the information that encodes our future selves would soon be packed into hardware and software rather than DNA. The Impact Analysis Angela Aristidou, who studies the real-life deployment of AI at University College London, is not surprised that Moravec’s book is enjoying a revival. She says that what in 1988 might have read like science fiction – and still might to most of us – looks eminently realisable to those in the know. The Prediction Hanson shares his conviction that the revolution is inevitable, as soon as AI attains something experts agree to call human-level intelligence. “We are going to generate an explosion of things like us in the future, who will be different from us in many ways,” Hanson says. “To the extent that they have minds somewhat like ours, they are our mind children.”

Australia faces a rapidly ageing population and chronic shortages of aged‑care staff, driving an emerging industry of AI‑enabled robots, virtual‑reality experiences and other digital tools aimed at improving resident wellbeing.AI and Robotics in Australian Aged Care: Current LandscapeProf Wendy Moyle, who runs the social‑robotics laboratory at Griffith University, argues that technology should support humans rather than replace them. She points to a Chinese virtual hospital as a sign of rapid progress, while warning that many inventions are built without input from health professionals or end‑users.Demographic Trends Driving Demand for Tech SolutionsAustralia’s population is ageing, increasing demand for residential and home‑based care.Workforce shortages in aged‑care facilities exacerbate challenges of neglect and abuse.Technology is not a magic bullet, but pilots show measurable benefits for mood, cognition and social isolation.How Tech Is Shaping Human Connection in Care HomesAt St Vincent’s Care in Toowoomba, residents board the “St Vincent’s Express” – a replica train station and carriage that combines physical sets with screens showing Alpine scenery. Manager Elzette Lategan says the experience “takes boredom, loneliness and isolation away and brings in hope.”The organisation Aged Care Research and Industry Innovation Australia notes that virtual reality can improve mood, memory, problem‑solving and spatial awareness, and may reduce pain and anxiety.Companion robots such as Abi, produced by Andromeda, use AI and machine‑learning to recognise faces, interpret emotions and remember conversations, speaking in 90 languages to cater to diverse residents.Future Outlook: Integrating AI While Preserving HumanityMoyle cautions that Australia must “think outside the square,” ensuring that tech augments the human touch rather than substituting it. Continued collaboration between engineers, clinicians and residents will be essential to scale innovations that genuinely enhance quality of life for older Australians.

The Rise of Nigeria's Digital Herbal Marketplace In Abuja, Nigeria, Oke Bola thought a fertility supplement she found online might help her conceive. Instead, within days of taking it, she struggled to breathe. Her experience reflects a growing online trade in unverified herbal remedies promoted across social media platforms. Bola, who is in her early 40s and has never had children, bought the supplement earlier this year and increased the recommended dosage, hoping for quicker results after hearing about it from friends and family. "I recognised the symptoms of asthma; the wheezing sound at night was familiar," she told Al Jazeera. "When I checked online, I realised it could be from the herbal medication." Her experience is not isolated. Across Nigeria, doctors and pharmacists report a surge in social media-driven self-medication, particularly involving unverified herbal products. This trend is worsening health outcomes, delaying treatment, and adding pressure to an already strained healthcare system serving about 230 million people. Nigeria's young, hyperconnected population increasingly uses digital platforms for health information and advice. But that access has also created what Dr Isaac Kolawole and Dr Fidelis describe as an "algorithmic apothecary" – an unregulated online marketplace where influencers and anonymous sellers promote remedies directly to consumers with little or no scientific backing. Health Impacts of Unverified Herbal Remedies Within this ecosystem, herbal remedies, long part of Nigeria's medical and cultural landscape, are increasingly repackaged as miracle cures, sometimes with dangerous consequences. Doctors report more patients arriving at hospitals only when their conditions have significantly worsened, often after prolonged use of unverified treatments. A consultant nephrologist at the University College Hospital in Ibadan, Dr Yemi Raji, said herbal medicine continues to play a role in kidney disease cases in Nigeria. "When you take herbal medication, you are taking both the good and the bad," he said. "Patients often arrive late, when treatment is more difficult and expensive." Dialysis alone can cost between 50,000 and 100,000 naira ($36-72) per session, several times a week. Studies link herbal use to kidney and liver disease cases across Africa, including findings that about 46 percent of liver disease admissions in one Nigerian hospital involved herbs or roots. A 2022 study found that 76.65 percent of participants had used herbal medicine, with more than a third combining herbal and conventional treatments while 82.44 percent did not inform their doctors. The Algorithmic Amplification Effect On a smartphone screen, relief is just a click away: fertility tonics, eye drops promising restored vision, syrups claiming to "flush out" disease. The advertisements are polished, persuasive and constant, woven into TikTok, Facebook, Instagram and X feeds. "The platforms themselves amplify this effect," said Dr Egemba Chinonso Fidelis, a public health advocate known online as Aproko Doctor. "Their algorithms reward engaging content and push it to wider audiences." Even users who try to avoid such content often encounter it repeatedly, shaped by emotional storytelling, music and urgency-driven messaging. A 2025 Nigeria-based study on Jinja Herbal Mixture found it appeared safe for short-term use within tested dosage ranges, but researchers recorded biochemical changes at higher doses, including altered creatinine and sodium levels in test subjects, signs of possible kidney and liver stress. The study called for further research into long-term effects and interactions with conventional medicines. Regulatory Challenges in the Digital Age The National Agency for Food and Drug Administration and Control (NAFDAC) says it is working to track unregistered manufacturers, but enforcement remains difficult, especially online. "With the sheer volume of products online, enforcement has limited reach," said Isaac Kolawole, the southwest zonal director of NAFDAC. Many sellers use fake or incomplete addresses, making them difficult to trace. NAFDAC requires strict registration, testing and approval before herbal products can be sold or advertised, but regulation has not kept pace with online commerce. Fidelis argued that stronger regulation alone is not enough. "If there are no consequences for lying about healthcare online, people will keep doing it," he said. He noted that scammers have even used AI-generated versions of his image to promote fake products. "Real medicine does not promise to cure everything, and it does not rely on countdowns," he added. "Scammers do." Path Forward for Safer Digital Health As Nigeria's digital economy expands, the intersection of technology and healthcare will only grow more complex. Fidelis stressed that access to affordable healthcare must improve, public trust must be rebuilt, and digital platforms must take responsibility for the health content they amplify. Pharmacist Akinade Akinlolu noted that while conditions like diabetes and hypertension can be managed, online claims often suggest cures. "Economic pressure is also pushing people towards cheaper or 'miracle' alternatives," he added. "Without stronger safeguards," Fidelis warned, "the algorithmic apothecary will continue to grow and put more people at risk." The challenge for Nigeria's healthcare system is to harness the power of digital platforms while ensuring they promote evidence-based care rather than potentially harmful alternatives.